Renal Cell Carcinoma (RCC) is one of the most common and lethal kinds of kidney cancer. Approximately, one-third of all patients present with metastases at initial diagnoses. Although RCC is known to elicit a strong host immune response, the cancer has been deemed resistant to both immunotherapy and chemotherapy treatments. Unraveling the genes which regulate metastasis of RCC and the mechanism(s) by which is evades the host immune system may lead to improved biomarkers which guide therapy or prognosis. The investigation using basic science could lead to therapies which could improve the overall survival of patients with RCC.
Over 90% of RCC tumors from patients aberrantly express a cell surface glycoprotein known as Kidney Injury Molecule-1 (KIM-1) to varying extents. Our lab uses basic science and translational techniques to elucidate the pathophysiological role of KIM-1 in RCC, investigating both the role of KIM-1 in host immune evasion, as well as its role in metastasis.